Search Clinical Trials

Clinical Trials Search Results

The results of your search are listed below. To view the details of a trial or study, click on the see details >> link. Or start a new search.

Searched for: Lymphoma

46 results total

A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (anti-CD20) Antibody, Etoposide and Cyclophosphamide followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma

See details >>

Principal Investigator: Ajay Gopal, MD

Study Number: 1368.00

A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Non-Myeloablative Allogeneic Stem Cell Transplantation for Patients with Relapsed or Refractory Lymphoma - A Multi-Center Trial

See details >>

Principal Investigator: David Maloney, MD, PhD

Study Number: 1409.00

Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial

See details >>

Principal Investigator: Mohamed Sorror, MD, MSc

Study Number: 1840.00

A Clinical Trial Evaluating I131-Tositumomab (anti-CD20) with Escalating Doses of Fludarabine followed by Autologous or Syngeneic Stem Cell Transplantation for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma in Patients 60 Years of Age and Older

See details >>

Principal Investigator: Ajay Gopal, MD

Study Number: 1943.00

A Pilot Study to Evaluate the Safety and Feasibility of Cellular Immunotherapy Using Genetically Modified Autologous CD20-Specific T Cells For Patients With Relapsed or Refractory Mantle Cell and Indolent B Cell Lymphomas

See details >>

Principal Investigator: Brian Till, MD

Study Number: 2154.00

Addition of Pre- and Post-Transplant Rituximab to Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

See details >>

Principal Investigator: Andrew Rezvani, MD

Study Number: 2226.00

Phase I-II Study of Denileukin Diftitox (ONTAK®) in Patients with Advanced Refractory Breast Cancer

See details >>

Principal Investigator: Lupe Salazar, MD

Study Number: 6308

Phase I/II Clinical Trial Evaluating the Use of Vorinostat Combined with Paclitaxel and Radiotherapy in Patients with Inoperable Stage III Non-Small Cell Lung Cancer Unable to Tolerate Cisplatin

See details >>

Principal Investigator: Shilpen Patel, MD

Study Number: 6600

A Phase II Prospective Non-Randomized Two-Arm Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (CTCL) Who Did Not Receive Prior Systemic Therapy

See details >>

Principal Investigator: Andrei Shustov, MD

Study Number: 6914

A Phase III, Groupwide Study of Dose-Intensive, Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly-Diagnosed, Intermediate-Risk Hodgkin's Disease

See details >>

Principal Investigator: Rebecca Johnson, MD

Study Number: COG AHOD0031

Displaying first 10 of 46 total results. Click to view all 46 results.

Search Options

Select a disease from the list below:

Limit results to studies enrolling:
Both Adults & Pediatrics Adults Pediatrics

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N. PO Box 19024 Seattle, WA 98109
©2009 Fred Hutchinson Cancer Research Center, a nonprofit organization.
Terms of Use & Privacy Policy.